Published in BMJ on July 26, 2011
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol (2014) 2.88
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J (2013) 2.02
The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One (2013) 1.95
Aging, diabetes, and the public health system in the United States. Am J Public Health (2012) 1.94
Effects of 7 days on an ad libitum low-fat vegan diet: the McDougall Program cohort. Nutr J (2014) 1.50
Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med (2011) 1.39
Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care (2012) 1.12
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther (2013) 1.11
Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol (2012) 1.11
Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea. Diabetes Metab J (2011) 1.11
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation (2014) 1.05
Glycaemic control is improved by 7 days of aerobic exercise training in patients with type 2 diabetes. Diabetologia (2012) 1.03
Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. J Am Geriatr Soc (2013) 1.03
Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. Circ Cardiovasc Qual Outcomes (2016) 1.02
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci (2013) 0.99
A promising solution to enhance the sensocompatibility of biosensors in continuous glucose monitoring systems. J Diabetes Sci Technol (2013) 0.98
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther (2013) 0.98
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol (2016) 0.96
Hypoglycemia in type 2 diabetes: current controversies and changing practices. Front Endocrinol (Lausanne) (2012) 0.95
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol (2016) 0.94
Sex differences in all-cause and cardiovascular mortality, hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late. Diabetes Care (2013) 0.93
Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab (2014) 0.91
The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med (2016) 0.90
14-Year risk of all-cause mortality according to hypoglycaemic drug exposure in a general population. PLoS One (2014) 0.90
Glycemic control and cardiovascular disease: what's a doctor to do? Curr Diab Rep (2012) 0.89
Younger adult type 2 diabetic patients have poorer glycaemic control: a cross-sectional study in a primary care setting in Singapore. BMC Endocr Disord (2013) 0.89
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol (2015) 0.88
Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol (2013) 0.88
Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. J Diabetes Investig (2015) 0.87
Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol (2013) 0.87
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol (2013) 0.87
Endothelial insulin and IGF-1 receptors: when yes means NO. Diabetes (2012) 0.87
Association of glycation gap with mortality and vascular complications in diabetes. Diabetes Care (2013) 0.87
Recent HbA1c values and mortality risk in type 2 diabetes. population-based case-control study. PLoS One (2013) 0.86
SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes (2013) 0.86
Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience. Drugs (2016) 0.86
Effect of telehealth on glycaemic control: analysis of patients with type 2 diabetes in the Whole Systems Demonstrator cluster randomised trial. BMC Health Serv Res (2014) 0.86
Effect of exercise on blood pressure in type 2 diabetes: a randomized controlled trial. J Gen Intern Med (2012) 0.86
Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care. Diabet Med (2013) 0.86
Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis (2015) 0.86
Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice. Clin Sci (Lond) (2013) 0.85
Management of hyperglycemia in type 2 diabetes: evidence and uncertainty. Cardiovasc Diabetol (2013) 0.85
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care (2013) 0.85
Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice. Cardiovasc Diabetol (2014) 0.85
The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study. Cardiovasc Diabetol (2015) 0.85
A study of patients' perceptions of diabetes care delivery and diabetes: propositional analysis in people with type 1 and 2 diabetes managed by group or usual care. Diabetes Care (2011) 0.84
Antioxidant plants and diabetes mellitus. J Res Med Sci (2015) 0.83
Comorbid Heart Failure and Renal Impairment: Epidemiology and Management. Cardiorenal Med (2012) 0.83
Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol (2016) 0.83
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke (2017) 0.82
The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud (2014) 0.82
Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care (2013) 0.82
Intensive glucose lowering treatment in type 2 diabetes. BMJ (2011) 0.81
Diet control to achieve euglycemia induces significant loss of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats. Exp Mol Med (2014) 0.81
Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Am Heart Assoc (2015) 0.80
Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage. BMC Cardiovasc Disord (2014) 0.80
Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. SAGE Open Med (2015) 0.80
Increased risk of diabetes following perianal abscess: a population-based follow-up study. Int J Colorectal Dis (2012) 0.80
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. Vasc Health Risk Manag (2015) 0.79
Glucose control and cardiovascular outcomes: reorienting approach. Front Endocrinol (Lausanne) (2012) 0.79
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovasc Diabetol (2016) 0.79
Medication adherence and direct treatment cost among diabetes patients attending a tertiary healthcare facility in Ogbomosho, Nigeria. Malawi Med J (2015) 0.79
Intradermal insulin delivery: a promising future for diabetes management. J Diabetes Sci Technol (2014) 0.78
Stepwise self-titration of oral glucose-lowering medication using a mobile telephone-based telehealth platform in type 2 diabetes: a feasibility trial in primary care. J Diabetes Sci Technol (2013) 0.78
Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. BMC Med Res Methodol (2013) 0.78
Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus. Schizophr Bull (2015) 0.78
The Tibetan herbal medicines Padma 28 and Padma Circosan inhibit the formation of advanced glycation endproducts (AGE) and advanced oxidation protein products (AOPP) in vitro. BMC Complement Altern Med (2014) 0.77
Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. Cardiovasc Diabetol (2015) 0.77
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Ther (2016) 0.77
MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget (2015) 0.77
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study. Medicine (Baltimore) (2015) 0.76
Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. J Diabetes Res (2015) 0.76
A review of cardiovascular outcomes in the treatment of people with type 2 diabetes. Diabetes Ther (2014) 0.76
Arrow plots show results of meta-analyses of surrogate and clinical outcomes. BMJ (2011) 0.75
Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. Curr Diabetes Rev (2016) 0.75
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes. Diabetes Ther (2014) 0.75
Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers. Drug Target Insights (2016) 0.75
MicroRNA and hyperglycemic memory in the diabetic heart. J Thorac Dis (2016) 0.75
Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013. J Clin Med Res (2016) 0.75
Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials? Evid Based Med (2011) 0.75
A randomized controlled trial comparing treatment with oral agents and basal insulin in elderly patients with type 2 diabetes in long-term care facilities. BMJ Open Diabetes Res Care (2015) 0.75
Prevention of complications in type 2 diabetes: is drug glucose control evidence based? Br J Gen Pract (2017) 0.75
A Pilot Study to Assess the Feasibility of the Spanish Diabetes Self-Management Program in the Basque Country. J Diabetes Res (2016) 0.75
Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis. Lancet Diabetes Endocrinol (2016) 0.75
Grand challenges in diabetes. Front Endocrinol (Lausanne) (2012) 0.75
General practitioners' justifications for therapeutic inertia in cardiovascular prevention: an empirically grounded typology. BMJ Open (2016) 0.75
ACP Journal Club. Review: Intensive glucose lowering does not reduce mortality in type 2 diabetes. Ann Intern Med (2011) 0.75
Target values of cardiovascular risk factors are not associated with all-cause mortality in patients with type 2 diabetes mellitus. PLoS One (2015) 0.75
Update in internal medicine: intensive glucose lowering does not reduce mortality in type 2 diabetes mellitus. Maedica (Buchar) (2012) 0.75
Improved A1C and Lipid Profile in Patients Referred to Diabetes Education Programs in a Wide Health Care Network: A Retrospective Study. Diabetes Spectr (2014) 0.75
Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes. Hypertens Res (2016) 0.75
Cardioprotective role of insulin: Advantage analogues. J Res Med Sci (2012) 0.75
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Adv Ther (2016) 0.75
In reply. Dtsch Arztebl Int (2014) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 75.82
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract (1995) 12.51
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (2010) 11.55
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet (2009) 10.55
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet (2010) 8.27
Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia (2009) 6.55
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med (2009) 4.19
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med (2008) 3.54
Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med (1997) 3.35
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med (2009) 3.29
Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ (2000) 2.96
Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev (2006) 2.59
Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med (2010) 2.52
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol (2007) 2.15
Patient-important outcomes in registered diabetes trials. JAMA (2008) 2.00
Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J (1996) 1.83
What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. BMJ (2003) 1.49
The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes (1975) 1.43
The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications (2000) 1.33
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) Diabetes Care (1999) 1.32
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab (2009) 1.32
Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes (1982) 1.08
Should people at low risk of cardiovascular disease take a statin? BMJ (2013) 5.24
Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev (2012) 4.66
Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev (2009) 2.59
Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med (2006) 2.56
Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens (2010) 2.49
Statin adherence and risk of accidents: a cautionary tale. Circulation (2009) 2.47
J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med (2002) 2.45
Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev (2014) 2.23
Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia (2007) 2.13
Thiazolidinediones and fractures in men and women. Arch Intern Med (2009) 1.98
Reliability and validity of opiate use self-report in a population at high risk for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev (2004) 1.95
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med (2012) 1.85
Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care (2011) 1.78
Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis (2013) 1.77
Both extrauterine and intrauterine growth restriction impair renal function in children born very preterm. Kidney Int (2009) 1.70
Effect of periodic letters on evidence-based drug therapy on prescribing behaviour: a randomized trial. CMAJ (2004) 1.67
Overall accuracy of the BpTRU--an automated electronic blood pressure device. Blood Press Monit (2004) 1.64
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev (2008) 1.63
Lipid lowering efficacy of atorvastatin. Cochrane Database Syst Rev (2012) 1.62
Better Prescribing Project: a randomized controlled trial of the impact of case-based educational modules and personal prescribing feedback on prescribing for hypertension in primary care. Fam Pract (2004) 1.58
Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev (2012) 1.57
High exposure to polycyclic aromatic hydrocarbons may contribute to high risk of esophageal cancer in northeastern Iran. Anticancer Res (2005) 1.57
Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev (2009) 1.54
Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens (2007) 1.51
Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event. Cochrane Database Syst Rev (2009) 1.51
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev (2008) 1.44
Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension. Cochrane Database Syst Rev (2014) 1.41
Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension (2005) 1.41
Commitment to change statements can predict actual change in practice. J Contin Educ Health Prof (2003) 1.36
"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. BMJ (2005) 1.24
Informed consent document improvement does not increase patients' comprehension in biomedical research. Br J Clin Pharmacol (2010) 1.19
Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J Hypertens (2002) 1.18
Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. CMAJ (2012) 1.12
Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother (2009) 1.10
Drug safety without borders: concerns about bupropion. CMAJ (2002) 1.09
Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev (2008) 1.09
Improvement of the comprehension of written information given to healthy volunteers in biomedical research: a single-blind randomized controlled study. Fundam Clin Pharmacol (2007) 1.07
Patterns of food and nutrient consumption in northern Iran, a high-risk area for esophageal cancer. Nutr Cancer (2009) 1.07
Practice guidelines by specialist societies are surprisingly deficient. Int J Clin Pract (2007) 1.03
Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev (2012) 1.02
l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol (2011) 1.02
New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear. J Clin Epidemiol (2007) 0.98
First-line first? Trends in thiazide prescribing for hypertensive seniors. PLoS Med (2005) 0.98
Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Basic Res Cardiol (2015) 0.97
Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One (2009) 0.94
Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev (2013) 0.94
Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev (2009) 0.93
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev (2014) 0.92
Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale. PLoS One (2009) 0.92
Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev (2010) 0.91
Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Open Med (2010) 0.91
β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord (2013) 0.90
SCORE should be preferred to Framingham to predict cardiovascular death in French population. Eur J Cardiovasc Prev Rehabil (2009) 0.89
The global risk approach should be better applied in French hypertensive patients: a comparison between simulation and observation studies. PLoS One (2011) 0.87
Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database Syst Rev (2009) 0.87
Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev (2009) 0.87
Virtual patients and sensitivity analysis of the Guyton model of blood pressure regulation: towards individualized models of whole-body physiology. PLoS Comput Biol (2012) 0.87
Thyroglobulin measurement in fine-needle aspirates of lymph nodes in patients with differentiated thyroid cancer: a simple definition of the threshold value, with emphasis on potential pitfalls of the method. Clin Chem Lab Med (2010) 0.86
Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database Syst Rev (2012) 0.86
Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol (2003) 0.86
Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials. PLoS One (2009) 0.86
A European approach to clinical investigator training. Front Pharmacol (2013) 0.85
Comparison of the automated non-invasive oscillometric blood pressure monitor (BpTRU) with the auscultatory mercury sphygmomanometer in a paediatric population. Blood Press Monit (2004) 0.85
Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev (2014) 0.85
Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach. AAPS J (2013) 0.84
Impact of French 'Comités de Protection des Personnes' on the readability of informed consent documents (ICD) in biomedical research: more information, but not better information. Fundam Clin Pharmacol (2005) 0.84
Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence. Pediatrics (2014) 0.83
Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. Clin Pharmacokinet (2013) 0.83
Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev (2012) 0.82
Patient versus general practitioner perception of problems with treatment adherence in type 2 diabetes: from adherence to concordance. Eur J Gen Pract (2009) 0.82
Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. Fundam Clin Pharmacol (2005) 0.82
Quantity and quality of dietary fat, carbohydrate, and fiber intake in the German EPIC cohorts. Ann Nutr Metab (2003) 0.82
Anti-Trypanosoma cruzi cross-reactive antibodies detected at high rate in non-exposed individuals living in non-endemic regions: seroprevalence and association to other viral serologies. PLoS One (2013) 0.81
Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder. Two-year follow-up of a controlled pilot study. Psychother Psychosom (2009) 0.81
How should therapeutic information be transferred to users? Fundam Clin Pharmacol (2003) 0.81
Withdraw all COX-2-selective drugs. Med J Aust (2005) 0.81
Editorial comment--Secondary prevention of stroke: beyond meta-analyses. Stroke (2003) 0.80
Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev (2015) 0.80
Impaired baroreflex sensitivity and the risks of new-onset ambulatory hypertension, in an elderly population-based study. Int J Cardiol (2013) 0.80
Physicians' knowledge and practice of lung cancer screening: a cross-sectional survey comparing general practitioners, thoracic oncologists, and pulmonologists in France. Clin Lung Cancer (2013) 0.80
Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test? Clin Endocrinol (Oxf) (2013) 0.80
Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. Antiviral Res (2012) 0.80
Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev (2010) 0.79
A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial. BMC Complement Altern Med (2010) 0.79
[Modeling of systolic blood pressure reaction to antihypertensive agents in people with hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi (2011) 0.79